We hypothesized that PD-1expressed by regulatory T cells (Tregs) would be functional and their expression levels may associate with activation status of CD4+ T and CD8+ T cells and the disease progression of HIV-1-infected patients. To prove it, we dynamically examined PD-1 expression levels by Tregs in peripheral blood of HIV-1-infected individuals not receiving antiretroviral therapy. Eighty-one HIV-1-infected individuals not undergoing antiretroviral therapy and 22 HIV-1-seronegative donors were enrolled in our study. Tregs were defined as CD4+CD25+CD127lo/− by flow cytometry. Expression of PD-1 and the activation markers CD38, HLA-DR, and Ki67 by Tregs and CD4+ T and CD8+ T cells was also determined by flow cytometry. TGF-β and IL-10 were measured to evaluate the suppressive function of Tregs. In all Tregs, the proportion of PD-1+ Tregs observed in HIV-1-infected persons was significantly greater than that seen in HIV-1-seronegative donors, and correlated with the activation of Tregs and CD4+ T and CD8+ T cells. This increased proportion of Tregs was also statistically associated with the disease progression. Blockade of PD-1/PD-L1 pathway with anti-PD-L1 mAb profoundly increased the level of intracellular TGF-β and IL-10 in CD4+CD25+CD127lo/− Tregs. Our data not only support that PD-1 plays a critical role to predict the activation status of cellular immunity and disease progression during HIV-1 infection but also indicate that blockade of PD-1/PD-L1 pathway represents a novel therapeutic approach to AIDS.
Get full access to this article
View all access options for this article.
References
1.
DouekDC, BrenchleyJM, BettsMR, et al.: HIV preferentially infects HIV-specific CD4+ T cells. Nature, 2002; 417:95–98.
2.
LevyJA: The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol, 2003; 24:628–632.
3.
ShevachEM, McHughRS, PiccirilloCA, ThorntonAM: Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev, 2001; 182:58–67.
4.
Suri-PayerE, AmarAZ, ThorntonAM, ShevachEM: CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol, 1998; 160:1212–1218.
5.
CaoW, JamiesonBD, HultinLE, HultinPM, DetelsR: Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses, 2009; 25:183–191.
6.
NilssonJ, BoassoA, VelillaPA, et al.: HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood, 2006; 108:3808–3817.
7.
SuchardMS, MayneE, GreenVA, et al.: FoxP3 expression is upregulated in CD4+ T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One, 2010; 5:e11762.
8.
MahnkeK, SchönfeldK, FondelS, et al.: Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer, 2007; 120:2723–2733.
9.
ChenYL, FangJH, LaiMD, ShanYS: Depletion of CD4+CD25+ regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. World J Gastroenterol, 2008; 14:5797–5809.
10.
ChaseAJ, SedaghatAR, GermanJR, et al.: Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol, 2007; 81:12748–12757.
11.
PiccirilloCA: Regulatory T cells in health and disease. Cytokine, 2008; 43:395–401.
12.
NakamuraK, KitaniA, StroberW: Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med, 2001; 194:629–644.
13.
HuberS, SchrammC, LehrHA, et al.: Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol, 2004; 173:6526–6531.
14.
NakamuraK, KitaniA, FussI, et al.: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol, 2004; 172:834–842.
15.
HaraM, KingsleyCI, NiimiM, et al.: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol, 2001; 166:3789–3796.
16.
AnnackerO, Pimenta-AraujoR, Burlen-DefranouxO, BarbosaTC, CumanoA, BandeiraA: CD25+ CD4+ T cells regulate the expansion of peripheral CD4+ T cells through the production of IL-10. J Immunol, 2001; 166:3008–3018.
17.
WeissL, Donkova-PetriniV, CaccavelliL, BalboM, CarbonneilC, LevyY: Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4+ T-cell responses in HIV-infected patients. Blood, 2004; 104:3249–3256.
18.
AandahlEM, MichaëlssonJ, MorettoWJ, HechtFM, NixonDF: Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol, 2004; 78:2454–2459.
19.
MaierH, IsogawaM, FreemanGJ, ChisariFV: PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol, 2007; 178:2714–2720.
20.
ZhangZ, ZhangJY, WherryEJ, et al.: Dynamic programmed death 1 expression by virus-specific CD8+ T cells correlates with the outcome of acute hepatitis B. Gastroenterology, 2008; 134:1938–1949, 1949.e1–1949.e3.
21.
DayCL, KaufmannDE, KiepielaP, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006; 443:350–354.
22.
SauceD, AlmeidaJR, LarsenM, et al.: PD-1 expression on human CD8+ T cells depends on both state of differentiation and activation status. AIDS, 2007; 21:2005–2013.
23.
D'SouzaM, FontenotAP, MackDG, et al.: Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol, 2007; 179:1979–1987.
24.
TrautmannL, JanbazianL, ChomontN, et al.: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med, 2006; 12:1198–1202.
25.
ElrefaeiM, BakerCA, JonesNG, BangsbergDR, CaoH: Presence of suppressor HIV-specific CD8+ T cells is associated with increased PD-1 expression on effector CD8+ T cells. J Immunol, 2008; 180:7757–7763.
26.
FreemanGJ, WherryEJ, AhmedR, SharpeAH: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med, 2006; 203:2223–2227.
27.
LichterfeldM, MouD, CungTD, et al.: Telomerase activity of HIV-1-specific CD8+ T cells: Constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood, 2008; 112:3679–3687.
28.
BettsMR, NasonMC, WestSM, et al.: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006; 107:4781–4789.
29.
PattanapanyasatK, ThakarMR: CD4+ T cell count as a tool to monitor HIV progression & anti-retroviral therapy. Indian J Med Res, 2005; 121:539–549.
30.
DockrellDH, BadleyAD, Algeciras-SchimnichA, et al.: Activation-induced CD4+ T cell death in HIV-positive individuals correlates with Fas susceptibility, CD4+ T cell count, and HIV plasma viral copy number. AIDS Res Hum Retroviruses, 1999; 15:1509–1518.
31.
de WolfF, SpijkermanI, SchellekensPT, et al.: AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: Markers with reciprocal predictive value over time after seroconversion. AIDS, 1997; 11:1799–1806.
32.
PerfettoSP, MaloneJD, HawkesC, et al.: CD38 expression on cryopreserved CD8+ T cells predicts HIV disease progression. Cytometry, 1998; 33:133–137.
33.
BenitoJM, LópezM, LozanoS, MartinezP, González-LahozJ, SorianoV: CD38 expression on CD8+ T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses, 2004; 20:227–233.
34.
BelloG, Velasco-de-CastroCA, BongertzV, et al.: Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1. J Med Virol, 2009; 81:1681–1690.
35.
HoHN, HultinLE, MitsuyasuRT, et al.: Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol, 1993; 150:3070–3079.
36.
CombadèreB, BlancC, LiT, et al.: CD4+Ki67+ lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur J Immunol, 2000; 30:3598–3603.
37.
Dyrhol-RiiseAM, OhlssonM, SkarsteinK, et al.: T cell proliferation and apoptosis in HIV-1-infected lymphoid tissue: Impact of highly active antiretroviral therapy. Clin Immunol, 2001; 101:180–191.
38.
ZhangJY, ZhangZ, WangX, et al.: PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood, 2007; 109:4671–4678.
39.
RosignoliG, LimCH, BowerM, GotchF, ImamiN: Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4+ and CD8+ T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol, 2009; 157:90–97.
40.
PetrovasC, CasazzaJP, BrenchleyJM, et al.: PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med, 2006; 203:2281–2292.
41.
FranceschiniD, ParoliM, FrancavillaV, et al.: PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest, 2009; 119:551–564.
42.
ParryRV, ChemnitzJM, FrauwirthKA, et al.: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol, 2005; 25:9543–9553.
43.
OestreichKJ, YoonH, AhmedR, BossJM: NFATc1 regulates PD-1 expression upon T cell activation. J Immunol, 2008; 181:4832–4839.
44.
HokeyDA, JohnsonFB, SmithJ, et al.: Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol, 2008; 38:1435–1445.
45.
FontenotJD, GavinMA, RudenskyAY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 2003; 4:330–336.
46.
HoriS, NomuraT, SakaguchiS: Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003; 299:1057–1061.
47.
KhattriR, CoxT, YasaykoSA, RamsdellF: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 2003; 4:337–342.
48.
LiuW, PutnamAL, Xu-YuZ, et al.: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med, 2006; 203:1701–1711.
49.
SeddikiN, Santner-NananB, MartinsonJ, et al.: Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med, 2006; 203:1693–1700.
50.
ShenLS, WangJ, ShenDF, et al.: CD4+CD25+CD127low/− regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clin Immunol, 2009; 131:109–118.
51.
Hartigan-O'ConnorDJ, PoonC, SinclairE, McCuneJM: Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods, 2007; 319:41–52.
52.
BanhamAH: Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells. Trends Immunol, 2006; 27:541–544.
53.
Del Pozo-Balado MdelM, LealM, Méndez-LagaresG, PachecoYM: CD4(+)CD25(+/hi)CD127(lo) phenotype does not accurately identify regulatory T cells in all populations of HIV-infected persons. J Infect Dis, 2010; 201:331–335.
54.
Golden-MasonL, PalmerB, KlarquistJ, MengsholJA, CastelblancoN, RosenHR: Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol, 2007; 81:9249–9258.
55.
ZhangJY, ZhangZ, JinB, et al.: Cutting edge: Programmed death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limited hepatitis B virus infection. J Immunol, 2008; 181:3741–3744.
56.
LukensJR, CruiseMW, LassenMG, HahnYS: Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol, 2008; 180:4875–4884.
57.
JenabianMA, PatelM, KemaI, et al.: Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One, 2013; 8:e78146.
58.
ChenJ, XunJ, YangJ, et al.: Plasma indoleamine 2,3-dioxygenase activity is associated with the size of HIV reservoir in patients receiving antiretroviral therapy. Clin Infect Dis, 2018; XX(XX):1–8.
59.
ChevalierMF, WeissL: The split personality of regulatory T cells in HIV infection. Blood, 2013; 121:29–37.
60.
KleinmanAJ, SivanandhamR, PandreaI, ChougnetCA, ApetreiC: Regulatory T cells as potential targets for HIV cure research. Front Immunol, 2018; 9:734.
61.
EvansVA, van der SluisRM, SolomonA, et al.: Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS, 2018; 32:1491–1497.
62.
TeiglerJE, LeyreL, ChomontN, et al.: Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. JCI Insight, 2018; 3:e98420.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
